1. Singapore Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Cordlife Group Limited

Cordlife Group Limited

CLIFF
Cordlife Group LimitedUS flagOther OTC
0.10
USD
- -
- -
26.25MMarket Cap
Cordlife Group Limited
CLIFF
(Other OTC)

Recent

price

0.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.17
0.18
0.15
0.19
0.22
0.23
0.23
0.27
0.24
0.23
0.22
0.22
0.22
0.11
0.15
0.15
Revenue per Share
0.06
0.04
0.06
0.12
0.12
0.05
-0.01
0.01
0.03
0.03
0.02
0.02
0.01
-0.07
-0.05
-0.05
Basic EPS, GAAP
0.03
0.02
0.03
0.01
-0.02
-0.04
0.01
0.03
0.04
0.06
0.03
0.02
0.03
-0.06
-0.01
-0.01
Free Cash Flow per Basic Share
- -
0.03
0.03
0.02
0.02
0.14
- -
- -
- -
0.01
0.01
0.01
- -
- -
- -
- -
Dividend per Share
0.28
0.42
0.34
0.58
0.67
0.58
0.59
0.21
0.62
0.63
0.65
0.65
0.66
0.59
0.54
0.53
Book Value per Share
0.27
0.41
0.33
0.54
0.61
0.46
0.45
0.31
0.38
0.4
0.41
0.41
0.42
0.35
0.3
0.29
Tangible Book Value per Share
151
172
233
257
260
259
259
253
254
254
255
256
256
256
256
256
Basic Weighted Avg Shares
26
30
35
49
58
60
60
68
62
59
57
55
56
28
39
38
Sales/Revenue/Turnover
28.09
18.28
21.13
17.67
9.51
1.76
-0.33
4.73
-5.42
7.58
7.06
2.22
-0.73
-87.18
-38.19
-36.68
Operating Margin (%)
1
1
1
2
2
3
3
3
4
4
4
4
4
4
4
4
Depreciation Expense
8
7
13
31
32
12
-3
3
6
7
6
5
4
-19
-13
-13
Net Income, GAAP
14.68
10.98
7.38
4.63
3.44
5.7
- -
26.4
20.47
13.26
12.47
11.21
16.25
- -
- -
- -
Effective Tax Rate (%)
33.02
22.88
38.86
62.18
56.37
20.68
-4.29
4.79
10.51
11.1
10.83
8.86
6.32
-67.11
-32.53
-33.31
Profit Margin (%)
5
21
10
42
30
131
67
82
57
77
76
87
80
66
56
48
Working Capital
- -
2
6
8
125
76
7
4
5
6
1
1
2
1
1
1
LT Debt
41
71
78
141
162
133
130
121
129
133
137
134
136
119
104
102
Total Equity
- -
8.42
8.58
6.94
2.37
0.39
- -
1.79
-2.03
2.86
2.56
0.82
-0.25
- -
- -
- -
Return on Invested Capital (%)
- -
11.74
16.78
25.04
16.1
6.48
- -
3.19
6
4.1
3.75
2.98
2.16
- -
- -
- -
Return on Capital (%)
- -
12.01
17.69
26.8
20.08
7.55
-1.69
3.15
6.11
4.11
3.77
2.95
2.09
-11.63
-8.72
-18.64
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
4
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
256
256
256
Market Capitalization
41
23
23

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
77
85
79
Cash, Cash Equivalents & STI
43
51
45
Accounts Receivable, Net
27
25
25
Inventories
1
1
1
Total Current Liabilities
28
29
31
Payables & Accruals
- -
- -
- -
ST Debt
1
1
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.98%
-4.53%
-11.95%
Free Cash Flow
-25.02%
-92.51%
-90.94%
Net Income, GAAP
-102.85%
-143.46%
-32.36%
Sales/Revenue/Turnover
-1.21%
-3.21%
39.54%
Total Cash Common Dividend
- -
- -
-2.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
10
8
- -
28
2025
10
10
10
9
39
2026
9
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.02
- -
-0.07
2025
-0.01
- -
-0.01
-0.02
-0.05
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Imagion Biosystems Limited (IBXXF)
Genetic Technologies Limited (GNTLF)
Twist Bioscience Corporation (TWST)
Neuronetics, Inc. (STIM)
Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
Devyser Diagnostics AB (publ) (DVYSR.ST)
Business
Cordlife Group Limited operates as an investment holding company, primarily providing specialized healthcare services focused on maternal and child health across Asia. The company maintains a significant operational footprint in Singapore, Hong Kong, India, Indonesia, Malaysia, and the Philippines, further extending its reach into markets like Thailand, Myanmar, and Vietnam through various affiliations. Its business structure encompasses two main divisions: Banking and Diagnostics. The Banking segment delivers comprehensive services for the processing and cryogenic storage of stem cells derived from cord blood, cord lining, cord tissue, and even placenta, alongside corneal lenticule banking. Meanwhile, the Diagnostics segment offers a wide array of genetic screening and testing solutions, including non-invasive prenatal evaluations, newborn metabolic and vision screenings, and advanced genetic analyses for talent and health predispositions. It also provides preimplantation genetic screening and endometrial receptivity assessments. The company has recently navigated considerable operational scrutiny, including a notice of intent from the Singapore Ministry of Health in September 2025 for a one-year suspension of its cord blood banking services, citing continued non-compliance with regulatory standards in critical operational aspects following earlier service resumptions. Cordlife Group Limited was established in 2001 and is based in Singapore.